Dr. Sarah Frances Vaulman, DO

Dr. Vaulman practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Vaulman's NPI, 1356769079, was assigned on March 31, 2014. Dr. Vaulman graduated from Kansas City University of Med & Biosciences, College of Osteo Med in 2014. Dr. Vaulman holds California license 20A18312.

Dr. Vaulman's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Vaulman's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. Dr. Vaulman is also affiliated with Los Robles Regional Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Vaulman to 1 more hospital and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vaulman practices, 3 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Vaulman's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dr. Vaulman is licensed in California.

CMS data shows 728 Medicare services from Dr. Vaulman across 4 procedure codes in 2024, for 233 Medicare patients. Medicare paid $72,410 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 233 Medicare patients who saw Dr. Vaulman in 2024. The largest group is 65 to 74, with 96 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 38% are also on Medicaid. Their average risk score is 3.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vaulman's median patient age at 68, with 48% women.

In 2024, Dr. Vaulman wrote 178 Medicare Part D claims for 75 patients. 88% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $133 in total drug cost. In 2022, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Vaulman for performance year 2024, reported as part of a group. Dr. Vaulman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vaulman as offering telehealth.

Dr. Vaulman graduated from Kansas City University of Med & Biosciences, College of Osteo Med in 2014.